Submission of newspaper publication w.r.t audited financial results for the financial year ended 31.03.2025
Awaiting price reaction for this filing.
Advik Laboratories, now renamed MPS Pharmaa Limited, has submitted copies of newspaper publications of its audited financial results for the quarter and full year ended 31 March 2025. The results were published on 29 May 2025 in Financial Express (English) and Jansatta (Hindi), as required under SEBI's Listing Obligations and Disclosure Requirements (Regulation 47 read with Regulation 33). The filings are a routine compliance disclosure submitted to BSE (Scrip Code 531686) and Ahmedabad Stock Exchange (Scrip Code 01636). The published results show the company posted a net loss of about ₹86.39 lakh in Q4 FY25 and a sharply wider full-year loss of around ₹17.14 crore in FY25, compared with a much smaller loss in FY24.
While the filing itself is only a regulatory compliance submission, the embedded results are negative — the FY25 full-year loss has ballooned significantly versus FY24, signalling continued and worsening financial stress for the company. This may weigh on shareholder sentiment and is likely to be viewed negatively by investors.